In the neoadjuvant setting, the CheckMate 816 trial led to the FDA and EMA approval of nivolumab plus platinum-based chemotherapy for patients with stage IB-IIIA NSCLC and a PD-L1 expression level greater than 1% [19,20]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.